Intercept soars as cardiovascular fears for NASH drug abated
This article was originally published in Scrip
Executive Summary
Intercept Pharmaceuticals shot up 57.7% in after-hours trading to $374 per share when the company disclosed new data on 11 August from a Phase II investigator-sponsored clinical trial for its lead drug obeticholic acid (OCA) in the treatment of non-alcoholic steatohepatitis (NASH), which seemed to alleviate investor fears about potential cardiovascular risks.